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Assess drug-resistance phenotypes, not just genotypes 
Standfirst: Whole genome sequencing is becoming the starting point for assessing the 
presence of known antimicrobial drug-resistance genes and identifying new resistance 
mechanisms in laboratory mutants and clinical isolates. However, without phenotypic 
characterization to confirm drug-resistance, caution needs to be taken in attributing 
relevance to any genes hitherto not shown to confer drug resistance. 
Laura JV Piddock 
Institute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham, 
UK. B15 2TT 
Email: l.j.v.piddock@bham.ac.uk 
 
Whole genome sequencing (WGS) is increasingly advocated as a diagnostic tool to identify 
the cause/s of infection and/or drug resistance.1 With rapid advances in sequencing 
technologies that address technical barriers to providing data about microorganisms in real 
time, WGS will soon be able to identify the cause of infections within a few hours of taking a 
sample from a patient. Known drug resistance genes, and virulence genes (e.g. that encode 
toxins), will also be quickly identified. For this technology to be fully embraced and 
embedded into clinical practice, the current challenge is to provide the non-specialist with 
user-friendly data analysis and reporting platforms that can reveal the presence of a 
pathogen, or pathogens in the case of polymicrobial infections, and resistance to achievable 
drug concentrations of clinically relevant drugs using internationally recognised 
standardised tests.2 For samples from some body sites, the ability to distinguish a 
pathogenic from commensal microorganisms of the same species is essential. This will 
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facilitate rapid reporting to healthcare practitioners and by informing them of the pathogen 
and drug resistance genes facilitate decision making in antimicrobial treatment options. 
There are numerous examples of whole genome sequencing and it’s utility in identifying the 
source of outbreaks of drug-resistant bacterial infections and/or their spread within the 
hospital environment, community or animals e.g. MRSA, Mycobacterium tuberculosis, 
Klebsiella pneumoniae and Salmonella.3 Quickly establishing the cause of hospital and 
community outbreaks of infection helps clinical decisions and infection control practices 
thereby helping to both treat the patient and eradicate microbial transmission. 
WGS is an extremely powerful tool that reveals in fine detail the evolution and transmission 
of drug resistant pathogens (e.g. de Been et al.4).  WGS is also excellent at identifying 
previously described transmissible drug resistance factors and single nucleotide 
polymorphisms (SNPs) and rearrangements in chromosomal genes. Searchable databases of 
bacterial drug resistance genes and SNPs have been developed, such as the comprehensive 
antibiotic resistance database (https://card.mcmaster.ca/),5 which allow researchers and 
others to quickly identify known mechanisms of drug resistance in their strains or isolates of 
interest. However, caution should be exercised in concluding that the presence of known 
drug resistance genes in a whole genome sequence means that this confers the phenotype.  
This is because a drug resistance gene may not cause a clinically relevant level of resistance, 
meaning that treatment with the antimicrobial may still be possible. Furthermore, our 
knowledge of drug resistance mechanisms is incomplete and there are occasions when the 
WGS of a microorganism does not reveal the mechanism. For this reason, a genome 
sequence should be seen as only the first stage in uncovering new drug-resistance 
mechanisms. For instance, we recently described a post-therapy multidrug resistant clinical 
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isolate of Salmonella enterica serovar Typhimurium;6 despite it containing known resistance 
genes, none were shown to confer the phenotype. We uncovered a SNP in a multidrug 
resistance (MDR) transporter gene, acrB. However, it took several years’ research by a 
multidisciplinary team to show that this SNP conferred MDR. 
Another example where the WGS did not reveal any known drug resistance genes was in 
our study of fluoroquinolone-resistant Streptococcus pneumoniae. We and two other 
research groups independently described SNPs in a gene encoding a predicted attenuator of 
transcription of the downstream genes encoding the ABC transporters PatA and PatB 7-9, but 
it was the laboratory experiments that confirmed this new mechanism of drug-resistance.7 
However, more challenging was identification of a gene duplication in S. pneumoniae that 
conferred drug resistance,10 again via increased production of PatA and PatB. Increasing 
gene copy number by duplication to confer resistance has been described in transmissible 
elements from numerous bacterial species and for numerous drugs (see Table 1 ref. 11). 
Likewise, genomic duplications are now a recognised mechanism of drug resistance for 
several drugs and bacterial species, including sulphonamides, trimethoprim and beta-
lactams in Escherichia coli11. Identifying this type of mechanism will be challenging for those 
who wish to use using WGS routinely in the clinic as a means to identifying drug resistances 
and will require a different type of data analysis. 
Genome-wide association studies (GWAS) bring together the phenotype of all members of a 
(large) collection of cell types (eukaryotic and prokaryotic) and their WGSs. These data are 
statistically analysed to identify specific genetic traits that associate with particular 
phenotypes. It has therefore been suggested that GWAS is a tool that will allow us to 
identify new drug resistance mechanisms. A proof of principle GWAS with S. pneumoniae 
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indicated how genes associated with drug resistance can be identified.12 Retrospective 
analysis of stored genome sequences in several different countries revealed that the 
transmissible colistin-resistance gene, mcr-1, was widely disseminated prior to first 
description in 2015. This gene may have been found sooner if GWAS had been applied; such 
analysis could still reveal the true origin of mcr-1 as it may not have emerged in China, or in 
animals, and then spread globally. It could have emerged on several occasions, as have the 
CTX-M family of extended-spectrum beta-lactamase (ESBL) genes.13  
However, when a drug resistance trait occurs rarely, only once it has been amplified in a 
population by bacterial spread or horizontal gene transmission will GWAS be useful.  For 
instance, if WGS was the sole method to detect drug resistance the early identification of 
NDM-1 mediated carbapenem-resistance in Gram-negative bacteria would have been 
unlikely. Data arising from WGS would have indicated such bacteria as being drug-
susceptible leading to the continued use of ineffective drugs.  
One strength of GWAS is that it uses isolates from humans, animals and/or the 
environment, and which have arisen due to evolutionary pressures such as drug exposure. 
Recently, GWAS became a realistic option to find new traits not previously associated with 
drug resistance14 with the identification of an outer membrane protein involved in 
resistance to the drug cefazolin in E. coli. GWAS will be particularly useful to identify those 
genetic traits that give rise to microbial survival in low drug concentrations that accumulate 
and then predispose strains to full drug resistance15. Another strength of GWAS is that it will 
identify those traits that individually have a small impact upon drug susceptibility, but 
together act epistatically to give drug resistance. Nonetheless, where GWAS is employed, 
careful experimentation will be required to confirm that the identified genomic changes 
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confer the drug-resistance phenotype and that it is clinically relevant. Some traits may be 
compensatory genomic changes that allow any fitness cost associated with drug resistance 
to be ameliorated.  
The provision of WGS datasets as freely accessible, large reference libraries of genomes, and 
the rapid advance in data analysis tools will ultimately allow the identification of the full 
repertoire of mechanisms of drug resistance including for bacteria that undergo frequent 
genetic recombination. With the technological advances reducing time and cost of WGS, 
this will then facilitate the rapid identification of drug resistances, increased adoption of 
genomics in clinical microbiology laboratories and give healthcare practitioners confidence 
in using genomic information to guide antibiotic treatment. This will help improve 
antimicrobial stewardship and so preserve the effectiveness of current and new drugs. Until 
that time, however, conventional drug susceptibility testing (phenotyping) using recognized 
standardized procedures (e.g. EUCAST or CLIS) will remain the mainstay in identifying novel 
resistances of clinical relevance in many bacteria, particularly Gram-negatives. This is 
because these methods use cut-off values that distinguish drug-susceptibility or 
intermediate-drug-susceptibility from clinically relevant levels of drug-resistance. However, 
for species where there is little or no horizontal gene transfer and drug resistance is due to a 
genomic change, such as in M. tuberculosis, and where time is of the essence to inform drug 
treatment decisions, where it is available the use of WGS will replace conventional 
methodologies. 
With the likelihood of the increasing use of genomic datasets to identify known and new 
drug resistances, it is now important that a guiding set of principles is introduced that 
indicate the steps that should be taken to confirm that any newly described genetic 
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change/s confer the associated or predicted drug resistance phenotype in any 
microorganism. In the same way that it was necessary to identify the properties that define 
a pathogen, Koch’s postulates,16 the same is true for new drug resistances. Having identified 
the putative drug-resistance trait, four antimicrobial drug resistance postulates are 
proposed. It is recommended that a drug resistance trait should only be described as such if 
the criteria of all postulates are met. These are that the genetic trait must be present in all 
drug-resistant microorganisms, and not present/not expressed in drug-susceptible strains. 
Replacing the genetic trait with the wild type DNA sequence should confer drug-
susceptibility, and introduction of the genetic trait into a drug susceptible strain should 
confer drug-resistance (Box 1).  Where two or more traits are proposed to be necessary to 
confer drug-resistance, either because they work in an additive manner or synergistically, 
the postulates should be met for all traits in the predicted combination. Adhering to these 
postulates will prevent misidentification or mis-attribution of genetic traits as conferring 
drug resistance. 
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Box. Proposed antimicrobial drug resistance postulates. 
A drug resistance trait should only be described as such if the criteria of these four postulates 
are met: 
1. Show genetic trait is present in drug-resistant microbes. 
2. Demonstrate that genetic trait is not present/not expressed in drug-susceptible 
strains.  
3. Replace the genetic trait with wild type DNA sequence and show that it confers drug-
susceptibility. 
4. Introduce the genetic trait into a drug susceptible strain and show that it confers 
drug resistance.  
